Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years in high-risk patient population

NATICK, Mass., and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced four-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system -- which is not approved for commercial distribution -- were maintained at four years with no new stent thrombosis reported after two years. Analysis of the data was presented by Professor Eberhard Grube, M.D., Heart Center Siegburg, Germany, the Co- Principal Investigator of the trial. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

"Even though the moderate-release TAXUS formulation, with an 8-10 fold higher in vitro dose, was never commercialized, the excellent ongoing results in TAXUS VI further demonstrate the margin of safety of the commercial slow- release TAXUS stent now implanted in more than four million patients worldwide," said Paul LaViolette, Boston Scientific Chief Operating Officer. "With no stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population."

"The four-year results from TAXUS VI demonstrate that the safety and efficacy benefits associated with the moderate-release TAXUS paclitaxel- eluting stent system were maintained in patients with complex coronary artery disease at four years," said Professor Grube. "The performance of the TAXUS stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents."

The randomized, double-blind, co
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Until now, ... (relational tables) or unstructured data (document stores). SQL products ... products have basically managed the wide assortment of unstructured ... to work with Big Data is with a NoSQL ... the various aspects of all Big Data issues. ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 When David ... and long-time friend of Mark Brnovich, was asked to ... Republican nomination for the Attorney General seat in the ... quickly gathered the support of Cardinal Hall of Fame ... Cardinals Derek Kennard and Mark Walczak. Green, Kennard and ...
(Date:8/28/2014)... banker arrives at the emergency department with complaints ... alcohol every dayoften at business lunches, and at ... decided to quit drinking and had his last ... It,s a common scenario in emergency rooms across ... and develops withdrawal. , Withdrawal is a potentially ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... Inhibiting a protein involved in bone metabolism can delay the ... with a particular form of prostate cancer, a researcher will ... Professor Stphane Oudard, Head of ... says that his team,s research on the effects of the ...
... for prostate cancer will be unveiled at the 2011 ... Led by Dr David rsted at the Copenhagen University ... with benign prostate enlargement have an increased risk of ... shows that monitoring prostate-specific antigen levels can be used ...
... News) -- People,s bodies build up vitamin D through exposure ... live in areas of the United States with low sunlight ... who live in the same places. The researchers say ... change. "This study shows that across-the-board vitamin D recommendations just ...
... -- Although some studies have suggested that men can ... their voices, a new study appears to dispel that notion ... women are ovulating by examining changes in their voices over ... Unlike previous studies, the researchers behind the new study ...
... Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting ... killers. "It is a memorable day in the history ... table gives a strong sense of the burden it represents ... challenge for all nations in the world2", declared Professor Michel ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
Cached Medicine News:Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 2Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 3Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 4Health News:2 new cost-effective ways to predict prostate cancer 2Health News:2 new cost-effective ways to predict prostate cancer 3Health News:2 new cost-effective ways to predict prostate cancer 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:Depression After Cancer Keeps Some From Follow-Up Care 2
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: